申请人:Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.
公开号:EP3919491A1
公开(公告)日:2021-12-08
The present invention discloses an AKT inhibitor, and specifically relates to a compound represented by formula I or a pharmaceutically acceptable salt thereof. The present invention further provides a preparation method thereof, and the use thereof in prevention and/or treatment of a disease mediated by AKT protein kinase.
本发明公开了一种 AKT 抑制剂,具体涉及一种由式 I 代表的化合物或其药学上可接受的盐。本发明进一步提供了其制备方法,及其在预防和/或治疗由 AKT 蛋白激酶介导的疾病中的用途。